CoChat

Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring

Open access
Seligmann, Jenny F., Fisher, David J., Brown, Louise C., Adams, Richard A., Graham, Janet, Quirke, Philip, Richman, Susan D., Butler, Rachel, Domingo, Enric, Blake, Andrew, Yates, Emma, Braun, Michael, Collinson, Fiona, Jones, Rob, Brown, Ewan, de Winton, Emma, Humphrey, Timothy C., Parmar, Mahesh, Kaplan, Richard, Wilson, Richard H., Seymour, Matthew, Maughan, Timothy S., on behalf of the FOCUS4 Trial Investigators · 2021 · Journal of Clinical Oncology
Cited by 117

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

PURPOSE: Outcomes in RAS-mutant metastatic colorectal cancer (mCRC) remain poor and patients have limited therapeutic options. Adavosertib is the first small-molecule inhibitor of WEE1 kinase. We hypothesized that aberrations in DNA replication seen in mCRC with both RAS and TP53 mutations would sensitize tumors to WEE1 inhibition. METHODS: Patients with newly diagnosed mCRC were registered into FOCUS4 and tested for TP53 and RAS mutations. Those with both mutations who were stable or responding after 16 weeks of chemotherapy were randomly assigned 2:1 between adavosertib and active monitoring (AM). Adavosertib (250 mg or 300 mg) was taken orally once on days 1-5 and days 8-12 of a 3-week cycle. The primary outcome was progression-free survival (PFS), with a target hazard ratio (HR) of 0.5 and 80% power with a one-sided 0.025 significance level. RESULTS: FOCUS4-C was conducted between April 2017 and Mar 2020 during which time 718 patients were registered; 247 (34%) were RAS/TP53-mutant. Sixty-nine patients were randomly assigned from 25 UK hospitals (adavosertib = 44; AM = 25). Adavosertib was associated with a PFS improvement over AM (median 3.61 v 1.87 months; HR = 0.35; 95% CI, 0.18 to 0.68; P = .0022). Overall survival (OS) was not improved with adavosertib versus AM (median 14.0 v 12.8 months; HR = 0.92; 95% CI, 0.44 to 1.94; P = .93). In prespecified subgroup analysis, adavosertib activity was greater in left-sided tumors (HR = 0.24; 95% CI, 0.11 to 0.51), versus right-sided (HR = 1.02; 95% CI, 0.41 to 2.56; interaction P = .043). Adavosertib was well-tolerated; grade 3 toxicities were diarrhea (9%), nausea (5%), and neutropenia (7%). CONCLUSION: In this phase II randomized trial, adavosertib improved PFS compared with AM and demonstrates potential as a well-tolerated therapy for RAS/TP53-mutant mCRC. Further testing is required in this sizable population of unmet need.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.21.01435

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 117

Metadata

Authors
Seligmann, J. F., Fisher, D. J., Brown, L. C., Adams, R. A., Graham, J., Quirke, P., Richman, S. D., Butler, R., Domingo, E., Blake, A., Yates, E., Braun, M., Collinson, F., Jones, R., Brown, E., de Winton, E., Humphrey, T. C., Parmar, M., Kaplan, R., Wilson, R. H., Seymour, M., Maughan, T. S., & on behalf of the FOCUS4 Trial Investigators
Venue
Journal of Clinical Oncology
Published
2021-11-20
Volume
39
Issue
33
Pages
3705-3715
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W3200898477
Cited by
117
References
2
FWCI
6.11
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring. https://app.cochat.ai/papers/10.1200/jco.21.01435
The paper
Seligmann, J. F., Fisher, D. J., Brown, L. C., Adams, R. A., Graham, J., Quirke, P., Richman, S. D., Butler, R., Domingo, E., Blake, A., Yates, E., Braun, M., Collinson, F., Jones, R., Brown, E., de Winton, E., Humphrey, T. C., Parmar, M., Kaplan, R., . . . on behalf of the FOCUS4 Trial Investigators. (2021). Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring. Journal of Clinical Oncology. https://doi.org/10.1200/jco.21.01435

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.